{
  "id": "52b2e1d8f828ad283c00000c",
  "type": "factoid",
  "question": "What is the indication of Daonil (Glibenclamide)?",
  "ideal_answer": "Glibenclamide is an antidiabetic and antiglycemic, used in severe NIDDM, and increasingly viewed as a rational alternative to insulin therapy.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/12460666",
    "http://www.ncbi.nlm.nih.gov/pubmed/22639778",
    "http://www.ncbi.nlm.nih.gov/pubmed/16922811",
    "http://www.ncbi.nlm.nih.gov/pubmed/6805141",
    "http://www.ncbi.nlm.nih.gov/pubmed/21608438",
    "http://www.ncbi.nlm.nih.gov/pubmed/10199151"
  ],
  "snippets": [
    {
      "text": "Metformin and glibenclamide are now increasingly viewed as a rational alternative to insulin therapy--a treatment both preferred by the women and a less expensive one, during pregnancy and breastfeeding.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22639778",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The effect of TFG on blood glucose were studied and the levels of lipid peroxidation [MDA (Malondialdehyde)] and antioxidant enzymes [SOD (Superoxide dismutase), GPx (Reduced Glutathione peroxidase)] were estimated and compared with standard drugs glibenclamide and insulin.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21608438",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Treatment with TFG, insulin and glibenclamide resulted in significantly reduced blood glucose in LM (8.71%) and HM (3.87%) in comparison with normal controls.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21608438",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Potency of TFG in restoring several parameters to normal values is comparable to glibenclamide, though not as efficient as insulin, an indication of its antihyperglycemic and antioxidant effect.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21608438",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "However, dietary supplementation with PB (6 g/kg extract for 4 weeks administered orally using an intragastric tube) ameliorated the alloxan-induced diabetes in a manner comparable with that of the reference antidiabetic drug glibenclamide",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16922811",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Moreover, the potassium-specific effects of both diazoxide and nicorandil on oxidative phosphorylation in skeletal muscle mitochondria were completely abolished by the antidiabetic sulfonylurea derivative glibenclamide, a well-known inhibitor of ATP-regulated potassium channels (K(ATP) channels).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12460666",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In mild NIDDM, gliclazide, tolbutamide or acetohexamide is used, and in more severe NIDDM glibenclamide is used.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/10199151",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "An improvement of the glucose tolerance could be observed up to 3 years, whereas after a 5-year glibenclamide therapy no certain influence on the glucose tolerance and insulin secretion could be proved.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/6805141",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In general the improvement of the glucose tolerance was not associated with an increased secretion of insulin, so that an extrapancreatic effect of glibenclamide (improvement of the peripheral insulin sensitivity?) seems to be possible.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/6805141",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "From clinical and practical point of view the findings would support the opinion that normal weight persons with IGT, particularly in already decreased insulin secretion, have an indication for a glibenclamide therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/6805141",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [
    "http://www.biosemantics.org/jochem#4275786",
    "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005905",
    "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006305"
  ],
  "exact_answer": "Diabetes mellitus"
}